Department of Pulmonary Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Department of Pulmonary Medicine, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Lung Cancer. 2014 Jan;83(1):90-6. doi: 10.1016/j.lungcan.2013.10.016. Epub 2013 Oct 30.
Fibroblast growth factor (FGF) 9 is a member of the FGF family, which modulates cell proliferation, differentiation, and motility. Recent studies show that the activation of FGF signals including FGF9 is associated with the pathogenesis of several cancers; however, its clinicopathological and biological significance in non-small cell lung cancer (NSCLC) is unclear. The purpose of this study was to clarify the characteristics of NSCLC with FGF9 expression.
We evaluated the expression of FGF9 in resected NSCLC specimens and corresponding non-tumorous lung tissue samples using cDNA microarray and evaluated its clinicopathological characteristics.
Nine out of 90 NSCLC specimens (10%) had "high" FGF9 expression compared with corresponding non-cancerous lung tissues. Histologically, of the 9 NSCLC specimens with high FGF9 expression, 5 were adenocarcinoma, whereas none were squamous cell carcinoma. FGF9 expression was not associated with sex, smoking history, or clinical stage. However, in patients with high and low FGF9 expression, the postoperative recurrence rates were 78% and 24% (p=0.033), respectively. Overall survival was significantly shorter in patients with high FGF9 expression than in those with low FGF9 expression (p<0.001).
Our data indicate that FGF9 may be a novel unfavorable prognostic indicator and a candidate therapeutic target of NSCLC.
成纤维细胞生长因子 9（FGF9）是 FGF 家族的成员，可调节细胞增殖、分化和迁移。最近的研究表明，FGF 信号的激活，包括 FGF9，与几种癌症的发病机制有关；然而，其在非小细胞肺癌（NSCLC）中的临床病理和生物学意义尚不清楚。本研究旨在阐明具有 FGF9 表达的 NSCLC 的特征。
我们使用 cDNA 微阵列评估了 90 例 NSCLC 标本和相应的非肿瘤性肺组织样本中 FGF9 的表达，并评估了其临床病理特征。
与相应的非癌性肺组织相比，90 例 NSCLC 标本中有 9 例（10%）表现为“高”FGF9 表达。组织学上，9 例高 FGF9 表达的 NSCLC 标本中，5 例为腺癌，而无一例为鳞状细胞癌。FGF9 表达与性别、吸烟史或临床分期无关。然而，在 FGF9 高表达和低表达的患者中，术后复发率分别为 78%和 24%（p=0.033）。FGF9 高表达患者的总生存期明显短于 FGF9 低表达患者（p<0.001）。
我们的数据表明，FGF9 可能是 NSCLC 的一种新的不良预后指标和候选治疗靶点。
